Retatrutide vs Semaglutide
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
Retatrutide (LY3437943) is described in the provided sources as a triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, with clinical development studies evaluating it in obesity and related conditions, and in type 2 diabetes. (PMIDs: 37366315, 37385280, 41090431)
Semaglutide is described in the provided sources as a GLP-1 receptor agonist, and as an once-weekly candidate developed by increasing albumin affinity to obtain prolonged exposure and action. The sources include clinical comparisons of semaglutide with tirzepatide (in type 2 diabetes and in obesity), with dulaglutide (SUSTAIN 7), and a review of semaglutide safety. The sources also describe semaglutide pharmacokinetics (half-life, exposure) and formulation context.
| Retatrutide | Semaglutide | |
|---|---|---|
| Family | GLP-1 & incretin agonists | GLP-1 & incretin agonists |
| Research goals | Metabolic & weight | Metabolic & weight |
| Amino acids | — | — |
| Molecular formula | — | C187H291N45O59 |
| Molecular weight | — | 4114 g/mol |
| CAS number | — | 910463-68-2 |
| Approx. half-life | — | — |
| Regulatory status | In clinical trials | FDA-approved drug |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 9 | 12 |
| Vendors independently tested | 20 | 20 |
| Best test score (Finnrick) | 8.4 | 84.0 |